Overview

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Status:
Completed
Trial end date:
2020-07-03
Target enrollment:
0
Participant gender:
All
Summary
Prospective, multicenter, randomized and open label study evaluating the benefit on renal function at 12 months post-transplantation, with an immunosuppression without calcineurin inhibitor at 3 months and combining mycophenolate sodium-Everolimus versus an immunosuppression combining Everolimus-Tacrolimus, in de novo renal transplant patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Poitiers University Hospital
Treatments:
Calcineurin Inhibitors
Everolimus
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus
Tacrolimus
Criteria
Inclusion Criteria:

- Patients receiving a first kidney transplant from a cadaveric or living donor

Exclusion Criteria:

- Double transplant

- Patient who has been treated with an immunosuppressive drug or study drug during the
four weeks before administration of the first dose of Everolimus